National Research Ethics Committee for Clinical Trials (NREC-CT)

Recruitment and informed consent procedure template

This template should be used by Sponsors of clinical trials as part of the Part II application dossier when Ireland is a Member State concerned.

Sections which are not appropriate should either be deleted or marked as Not Appropriate / NA.

This template was originally developed and endorsed by the EU Clinical Trials Expert Group to comply with Regulation (EU) No. 536/2014 Clinical Trials on Medicinal Products for Human Use and adapted by the National Office for Research Ethics Committees.

|  |
| --- |
| 1.0 All clinical trials (This section should be completed for all trials) |
| 1.1 How will potential participants be identified? (e.g. publicising the trial or via existing patient lists) |
| Click or tap here to enter text. |
| 1.2 What resources will be used for recruitment? (Describe the format of the resources, e.g. paper or electronic and how these will be presented to potential participants e.g. via the post, in the clinic, through social media or on the radio) |
| Click or tap here to enter text. |
| 1.3 Will identification of potential participants involve access to identifiable information?  If yes, describe what measures will be in place to ensure that access to this information will be lawful (in accordance with Member State requirements). |
| Click or tap here to enter text. |
| 1.4 Who will be approaching potential participants and who will be obtaining informed consent? (Describe the professional role and whether there is a prior clinical relationship with potential participants) |
| Click or tap here to enter text. |
| 1.5 When will free and informed consent be obtained? (Describe when and where informed consent will be obtained and how privacy will be ensured) |
| Click or tap here to enter text. |
| 1.6 How much time will potential participants (or their legal representative) be given to decide whether to participate? |
| Click or tap here to enter text. |
| 1.7 How will it be assured that potential participants (or their legal representative) have understood the information and that consent is informed? (This should include how the informational needs of individuals will be identified and addressed) |
| Click or tap here to enter text. |
| 1.8 What arrangements are in place to obtain informed consent from potential participants (or their legal representative) who do not speak the national language or may require additional interpretation support? |
| Click or tap here to enter text. |
| 1.9 How will it be ensured that participants can withdraw their consent at any point? (This should include how any potential consequences of consent withdrawal will be dealt with) |
| Click or tap here to enter text. |
| 1.10 Please provide any further information, in relation to the procedure for recruitment and informed consent for the clinical trial, which has not been provided elsewhere in this document. (It is recommended that you refer to national guidance to ensure that all required information has been provided) |
| Click or tap here to enter text. |
| 1.11 Please provide a clear indication of what the first step of recruitment is. |
| Click or tap here to enter text. |

|  |
| --- |
| 2.0 Clinical trials which will recruit adults lacking decision making capacity (Adults lacking decision making capacity may be recruited into clinical trials only where consent has been obtained from a legally designated representative and data of a comparable validity cannot be obtained in clinical trials involving participants who are competent to give informed consent. Where potential participants do lack capacity to consent, arrangements should be in place to involve them as much as possible in the decision to participate in the clinical trial. ) |
| 2.1 Provide justification for recruiting incapacitated adults (This should include details of the nature of the condition which has caused the person to be incapacitated and the relevance of this condition to the clinical trial) |
| Click or tap here to enter text. |
| 2.2 Who will assess and confirm whether a potential participant has the capacity to consent? |
| Click or tap here to enter text. |
| 2.3 Where capacity to consent will fluctuate or will be borderline, how will potential participants be involved in the decision to participate in the trial? (This should include how information will be tailored to ensure participants (potential and existing) are able to understand the information and also how participants who regain capacity will be consented to continue in the trial) |
| Click or tap here to enter text. |
| 2.4 How will a legal representative be identified? (This should include which roles could act as legal representative for this trial) |
| Click or tap here to enter text. |

|  |
| --- |
| 3.0 For clinical trials which will involve minors  (Minors may be recruited into clinical trials only where consent has been obtained from a guardian(s) with parental responsibility or designated legal representative and where the clinical trial is such that it can only be carried out on minors. The minor should take part in the informed consent procedure as much as would be appropriate based on age and mental maturity. Where it would be appropriate, please specify any different arrangements for different age ranges.) |
| 3.1 Provide justification for recruiting minors |
| Click or tap here to enter text. |
| 3.2 How will potential participants be involved in the decision to participate in the trial? (Describe arrangements for obtaining and recording assent, including who will be obtaining consent and details of their training and experience with children) |
| Click or tap here to enter text. |
| 3.3 How will a legal representative be identified? (This should include which roles could act as legal representative for this trial) |
| Click or tap here to enter text. |
| 3.4 How will participants be consented to continue in the trial when they reach the age of legal competence? |
| Click or tap here to enter text. |

|  |
| --- |
| 4.0 Clinical trials where consent witnessed by an impartial witness will likely be used.  (Where a participant is unable to write, consent may be given and recorded through appropriate alternative means in the presence of at least one impartial witness. The witness is required to sign and date the informed consent document.) |
| 4.1 Why is it expected that an impartial witness might be required? |
| Click or tap here to enter text. |
| 4.2 How will an impartial witness be identified? |
| Click or tap here to enter text. |
| 4.3 How will it be known that the potential participant gives their informed consent? |
| Click or tap here to enter text. |

|  |
| --- |
| 5.0 Clinical trials in an emergency situation  (Information on the clinical trial may be given and informed consent may be obtained after the decision to include the participant in the clinical trial. This is where the decision is taken at the time of the first intervention in accordance with the protocol and, due to the urgency of the situation, the person is unable to give consent, nor can a legal representative be identified.) |
| 5.1 Describe why it would not be possible to obtain consent from potential participants or a legal representative prior to recruiting into the clinical trial. |
| Click or tap here to enter text. |
| 5.2 What arrangements will be in place to obtain informed consent from the participant or from a legal representative, whichever can be obtained soonest? (Where a legal representative is expected to be required due to the participant not having capacity to consent, please also complete section 2 of this document) |
| Click or tap here to enter text. |
| 5.3 How will it be ensured that a potential participant has not expressed any previous objection to participate in the clinical trial? |
| Click or tap here to enter text. |

|  |
| --- |
| 6.0 For ‘cluster’ clinical trials  (Informed consent may be obtained by simplified means where this does not contradict national law, the methodology of the trial requires the randomisation of groups rather than individuals, the investigative medicinal product is being used in accordance with the terms of the marketing authorisation and there are no interventions other than standard treatment.) |
| 6.1 Describe how simplified informed consent will be obtained? |
| Click or tap here to enter text. |